| 4.065 -0.045 (-1.09%) | 11-11 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.24 | 1-year : | 6.12 |
| Resists | First : | 4.48 | Second : | 5.24 |
| Pivot price | 4.09 |
|||
| Supports | First : | 3.91 | Second : | 3.55 |
| MAs | MA(5) : | 3.98  |
MA(20) : | 4.12 |
| MA(100) : | 3.99 |
MA(250) : | 3.91 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 54.9 |
D(3) : | 49.1 |
| RSI | RSI(14): 49.8 |
|||
| 52-week | High : | 4.78 | Low : | 2.54 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ GNFT ] has closed above bottom band by 45.0%. Bollinger Bands are 8.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.23 - 4.25 | 4.25 - 4.27 |
| Low: | 4.01 - 4.04 | 4.04 - 4.06 |
| Close: | 4.03 - 4.07 | 4.07 - 4.1 |
Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.
Mon, 10 Nov 2025
GENFIT Collaborates with EVerZom to Advance Exosome-Based Therapy for ACLF - TipRanks
Mon, 10 Nov 2025
GENFIT Unveils Promising Preclinical Data for ACLF Treatment - TipRanks
Mon, 10 Nov 2025
GENFIT Enters Research Collaboration with EVerZom to Advance Exosome-based Regenerative Technology in ACLF - GlobeNewswire
Mon, 10 Nov 2025
GENFIT Presents Promising New Preclinical Data on - GlobeNewswire
Sun, 02 Nov 2025
Genfit announces intention to voluntarily delist ADSs from Nasdaq - MSN
Thu, 30 Oct 2025
Genfit (GNFT) Plans to Voluntarily Delist from Nasdaq - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 0.1 (%) |
| Shares Short | 22 (K) |
| Shares Short P.Month | 31 (K) |
| EPS | -0.92 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.04 |
| Profit Margin | -85.9 % |
| Operating Margin | 0.1 % |
| Return on Assets (ttm) | -8.6 % |
| Return on Equity (ttm) | -51.8 % |
| Qtrly Rev. Growth | -41.8 % |
| Gross Profit (p.s.) | 0.9 |
| Sales Per Share | 0.9 |
| EBITDA (p.s.) | -0.53 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -3 (M) |
| Levered Free Cash Flow | 2 (M) |
| PE Ratio | -4.47 |
| PEG Ratio | 0 |
| Price to Book value | 3.87 |
| Price to Sales | 4.5 |
| Price to Cash Flow | -60.32 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|